Quarterly Result5 Feb 2026, 02:08 pm
Marksans Pharma Ltd. Delivers Resilient Performance in Q3FY26 with 10.6% YoY Revenue Growth
AI Summary
Marksans Pharma Ltd. reported its financial results for the quarter and nine months ended December 31, 2025. The company recorded an operating revenue of Rs. 754.4 cr. in Q3FY26, a 10.6% YoY growth, attributed to strong traction in the US and UK markets. EBITDA margin expanded by 217 bps YoY to 21.3%. The company also took steps to strengthen its global footprint through new subsidiaries in Europe and Canada.
Key Highlights
- Revenue growth of 10.6% YoY in Q3FY26
- EBITDA margin expansion of 217 bps YoY
- New subsidiaries established in Europe and Canada
- Steady execution across key markets and improved seasonal demand
- Improving product mix and favorable currency movements